Research Sample bioBank

Can’t find what you’re looking for? Contact us.

Or, need help ordering? 805.528.4341

Filter Samples By:

Get Weekly Research Sample Updates in your Inbox:

Hepatitis C (HCV) Genotype 3 Clinical Research Samples

Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 3 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank. 

  • All Hepatitis C (HCV) Genotype 3 Sample Orders are Packaged for Delivery within 24 Hours. 
  • All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
  • Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
  • Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations. 
Showing 28 of 28 total samples
 (0)
Checkout
Advanced Data View:
Showing 28 of 28 total samples
Buy
Product IDSampleOriginMatrixVial (ml)QuantityPriceAgeGenderEthnicityStorage TempSample DateTest 1Test Data 1Sample Detail 1Test 2Test Data 2Sample Detail 2Test 3Test Data 3Product
Details
Price
Buy
Additional Information 1Additional Data 1Additional Detail 1Additional Information 2Additional Data 2Additional Detail 2Additional Information 3Additional Data 3Additional Information 4Additional Data 4Additional Detail 4Additional Information 5Additional Data 5Additional Detail 5Additional Information 6Additional Data 6Additional Detail 6Additional Information 7Additional Data 7Additional Detail 7
DLS12-6267Hepatitis C (HCV) Genotype 3AustraliaSerum1.0010.00$95.0047 YFWhite<-70°C21-Aug-13Viral LoadU/AInnogenetics Versant HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknownSymptomsNo symptoms
DLS12-6271Hepatitis C (HCV) Genotype 3ItalySerum1.0010.00$95.0056 YMWhite<-70°C05-Apr-13Real-Time PCR111,089 U/mLSiemens TruGene HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryTransfusionSymptomsDecreased appetite; FatigueAdditional TestingALT: 45; AST: 57; ALP: 247; LDH: 401; Bilirubin: 0.83; Serum Creatinine: 1.21 mg/dL; Hepatocellular CarcinomaHepatitis Serologyanti HCV+ (Abbott)
DLS12-6275Hepatitis C (HCV) Genotype 3ItalySerum1.003.00$95.0056 YFWhite<-70°C13-Feb-13Roche cobas440,000 IU/mLInnogenetics Versant HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryIV Drug AbuseSymptomsFatigue; Depression
DLS12-7485Hepatitis C (HCV) Genotype 3SpainCitrated Plasma1.008.00$40.0049 YMU/A<-70°C18-Apr-12Roche cobas404,479 IU/mLHCV Ct Value - 21Innogenetics INNO-LIPA3a $40.00SymptomsAsymptomaticHepatitis SerologyAnti-HCV S/CO - 6.28 (Abbott PRISM)
DLS13-02054Hepatitis C (HCV) Genotype 3AustraliaK2 EDTA Plasma1.001.00$95.0039 YFWhite<-70°C19-Jun-13Roche cobas241,000 IU/mLInnogenetics Versant HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryIV Drug Abuse SymptomsDepression
DLS13-02065Hepatitis C (HCV) Genotype 3AustraliaK2 EDTA Plasma1.001.50$95.0041 YMWhite<-70°C17-Apr-13Roche cobas10,200 IU/mLInnogenetics Versant HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryIV Drug Abuse SymptomsFatigue
DLS13-02066Hepatitis C (HCV) Genotype 3AustraliaK2 EDTA Plasma1.001.50$95.0048 YMWhite<-70°C08-May-13Roche cobas32,900 IU/mLInnogenetics Versant HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryIV Drug Abuse SymptomsFatigue
DLS13-03325Hepatitis C (HCV) Genotype 3SpainCitrated Plasma1.0012.00$40.0045 YFU/A< -70C29-Aug-12Roche cobas40,890 IU/mLHCV Ct Value - 23Innogenetics INNO-LIPA3a$40.00Abbott PRISM7.11 S/CoAnti-HCVIs Subject on Anti-Viral Therapy / TreatmentNo SymptomsAsymptomatic
DLS13-03327Hepatitis C (HCV) Genotype 3SpainCitrated Plasma1.0010.00$40.0057 YFU/A< -70C28-Feb-12Roche cobas30,850 IU/mLHCV Ct Value - 24Innogenetics INNO-LIPA3a$40.00Abbott PRISM7.75 S/CoAnti-HCVIs Subject on Anti-Viral Therapy / TreatmentNo SymptomsAsymptomatic
DLS13-03329Hepatitis C (HCV) Genotype 3SpainCitrated Plasma1.007.00$40.0049 YMU/A< -70C05-Jan-08Roche cobas5,889 IU/mLHCV Ct Value - 25Innogenetics INNO-LIPA3a$40.00Abbott PRISM10.54 S/CoAnti-HCVIs Subject on Anti-Viral Therapy / TreatmentNo SymptomsAsymptomaticOther Testing ResultsImmunoblot C100(4+) C33(4+) C22(4+) NS5(4+)
DLS13-03336Hepatitis C (HCV) Genotype 3SpainCitrated Plasma1.005.00$40.0042 YMU/A< -70C24-Nov-12Roche cobas816,427 IU/mLHCV Ct Value - 22Innogenetics INNO-LIPA3a$40.00Abbott PRISM5.71 S/CoAnti-HCVIs Subject on Anti-Viral Therapy / TreatmentNo SymptomsAsymptomatic
DLS13-05042Hepatitis C (HCV) Genotype 3VietnamK2 EDTA Plasma1.0015.00$95.0035 YMAsian< -70C09-Sep-13Roche cobas1,120,000 copies/mLGenotype by RT PCR1 | 3$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentYesInterferonAcquired Infection CategoryIV Drug Abuse SymptomsNo symptoms
DLS13-09608Hepatitis C (HCV) Genotype 3VietnamSerum1.007.00$95.0046 YMAsian< -70C19-Dec-13Roche cobas59,400 IU/mLReal-Time PCR3$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryTransfusion SymptomsDecreased appetite; Fatigue; Abdominal painAdditional TestingALT: 66 U/L; AST: 157 U/L; Bilirubin: 24.3 umol/L; Serum Creatinine: 81 umol/L Hepatitis SerologyHBsAg- (ECLIA Cobas 6000)
DLS13-16672Hepatitis C (HCV) Genotype 3ItalySerum1.005.00$95.0043 YMWhite< -70C12-Jun-13Real-Time PCR1,178,956 U/mLSiemens TruGene HCV3a$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryTransfusion; Piercing; TattooSymptomsFatigue; JaundiceAdditional TestingALT: 57; AST: 89; ALP: 42; LDH: 559; Bilirubin: 1.21; Serum Creatinine: 0.7 mg/dL; CirrhosisHepatitis Serologyanti HCV+2006
DLS14-05376Hepatitis C (HCV) Genotype 3VietnamSerum1.006.00$95.0040 YMAsian< -70C22-May-14Roche cobas24,800 copies/mLGenotype by RT PCR1 | 3$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentYesTenofovir 300 mg; Lamivudine 150 mg; Aluvia 200/50 mgAcquired Infection CategorySexual Transmission; IV Drug AbuseSymptomsNo symptomsAdditional TestingALT: 81; AST: 55; Serum Creatinine: 134 umol/LHepatitis SerologyHBsAg-; Anti HCV+ (Elisa)Co-InfectionsHIV+2004
DLS14-05406Hepatitis C (HCV) Genotype 3VietnamSerum1.008.00$95.0027 YMAsian< -70C18-Aug-14Roche cobas10,000,000 copies/mL10-Aug-14Genotype by RT PCR1 | 314-Oct-14$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryUnknownSymptomsDecrease appetite; Fatigue; JaundiceAdditional TestingALT: 343; AST: 368; Bilirubin: 20.7 umol/L; Serum Creatinine: 0.9 mg/dL13-Aug-14Hepatitis Serology Result
DLS14-07997Hepatitis C (HCV) Genotype 3VietnamSerum1.0011.00$95.0038 YMAsian<-70C12-Aug-15Roche cobas13,800,000 IU/mL7-Aug-15Real-Time PCR3$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategorySexual transmission SymptomsNo symptoms
DLS14-08050Hepatitis C (HCV) Genotype 3VietnamSerum1.004.00$95.0038 YMAsian<-70C14-May-15Roche cobas3,320,000 copies/mL10-Sep-10Real-Time PCR1 | 321-May-15$95.003-series HepB VaccineYesIs Subject on Anti-Viral Therapy / TreatmentYesZidovudine 300 mg, Lamivudine 150 mg, Efavirnez 100 mgAcquired Infection CategoryIV Drug Abuse SymptomsNo symptoms
DLS16-67477Hepatitis C (HCV) Genotype 3VietnamSerum1.006.00$95.0045 YMAsian<-70C17-Apr-17Roche Cobas1,600 IU/mL17-Apr-17Genotype by RT PCR319-Apr-17$95.003-Series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoNoneAcquired Infection CategoryUnknown SymptomsFatigue; JaundiceAdditional TestingALT: 62 U/L,AST: 41 U/L, Bilirubin: 14 umol/L, Serum Creatinine: 54 umol/L, Chronic HCV13-Apr-2017 Hepatitis SerologyHCV Ab +Co-InfectionsNone
DLS16-67616Hepatitis C (HCV) Genotype 3VietnamSerum1.004.00$95.0032 YMAsian<-70C03-Mar-17Roche Cobas4,830,000 IU/mL1-Mar-17Genotype by RT PCR38-Mar-17$95.003-Series HepB VaccineYesIs Subject on Anti-Viral Therapy / TreatmentYesTenofovir; Lamivudine; EfavirenzAcquired Infection CategoryIV Drug Abuse SymptomsDecreased appetite; Fatigue; Abdominal painAdditional TestingALT: 39 U/L, AST: 25 U/L , Bilirubin: 29 umol/L, Serum Creatinine: 78 umol/L, HCV 20121-Mar-2017 Hepatitis SerologyNoneCo-InfectionsHIV+28-May-12
DLS0025526Hepatitis C (HCV) Genotype 3South AfricaSerum1.009.00$95.0058 YMWhite<-70C23-Sep-15Roche cobas5,460,000 IU/mLViral LoadSiemens Versant Lipa3aGenotype$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryPiercing | Tattoo SymptomsFatigue; Decreased AppetiteAdditional TestingALT: 37; AST: 59; ALP: 204; Bilirubin: 26 umol/L; Serum Creatinine: 79 umol/L23-Sep-15Hepatitis SerologyU/ACo-InfectionsChronic HCV
DLS16-72205Hepatitis C (HCV) Genotype 3ItalySerum1.008.00$95.0052 YFWhite<-70C28-Sep-17Roche cobas4,880,000 IU/mL29-Jun-17Siemens TruGene HCV 5NC3a29-Jun-17HCV Date of Diagnosis29-Jun-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsFatigueAdditional TestingALT: 50 U/L | AST: 50 U/L | Bilirubin: 1.7 mg/dL | Serum Creatinine: 0.9 mg/dL | | Liver Cirrhosis from HCV9-Oct-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb+, 29-Jun-17Co-InfectionsNone
DLS16-72208Hepatitis C (HCV) Genotype 3ItalySerum1.008.00$95.0058 YFWhite<-70C14-Nov-17Roche cobas656,000 IU/mL8-Sep-17Siemens TruGene HCV 5NC3a8-Sep-17HCV Date of Diagnosis8-Sep-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsNo symptomsAdditional TestingALT: 32 U/L | AST: 64 U/L | ALP: 103 U/L | Bilirubin: 0.3 mg/dL | Serum Creatinine: 0.7 mg/dL | Chronic Hepatitis C22-Mar-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb+, 8-Sep-17Co-InfectionsNone
DLS16-72211Hepatitis C (HCV) Genotype 3ItalySerum1.009.00$95.0038 YMWhite<-70C26-Oct-17Roche cobas261,000 IU/mL26-Oct-17Siemens TruGene HCV 5NC3a26-Oct-17HCV Date of Diagnosis26-Oct-17$95.003-series HepB VaccineNoIs Subject on Anti-Viral Therapy / TreatmentNoAcquired Infection CategoryU/ASymptomsDepressionAdditional TestingALT: 74 U/L | AST: 49 U/L | LDH: 173 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 0.5 mg/dL | Chronic Hepatitis C23-Oct-17Diasorin Liaison Serology ResultsHBsAg-, HBsAb+, HBcAb+, HCVAb+, 23-Oct-17Co-InfectionsNone
DLS0025524Hepatitis C (HCV) Genotype 3ItalySerum1.008.00$95.0056 YMWhite<-70C12-Jan-18Roche cobas362,115 IU/mLHCV Viral LoadGenotype3a6-Nov-173-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsFatigueAdditional TestingBilirubin: 2.3 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C6-Nov-17Hepatitis SerologyHBsAg- | HBsAb- | HBcAb- | (CMIA)6-Nov-17Co-InfectionsNone
DLS0083216Hepatitis C (HCV) Genotype 3ItalySerum1.0012.00$95.0039 YMWhite<-70C29-Jun-18Roche cobas66,000 IU/mLHCV Viral LoadGenotype329-Jun-183-series HepB VaccineNo$95.00Acquired Infection CategoryU/AIs Subject on Anti-Viral Therapy / TreatmentNoCurrent SymptomsNo symptomsAdditional TestingBilirubin: 0.78 mg/dL | Creatinine: 0.7 mg/dL | Chronic Hepatitis C10-Jul-18Hepatitis SerologyHBsAg- | HBsAb+ | HBcAb+ | (CMIA)31-May-18Co-InfectionsNone
KHBR-1735Hepatitis C (HCV) Genotype 3USASerum2.251.00$95.0047 YMWhite<-70C16-Apr-18Roche COBAS | Taqman230,947HCV RNA PCR$95.00Freeze Date05.15.18HEP C+: Genotype 3
DLS0116317Hepatitis C (HCV) Genotype 3USASerum1.751.00$95.00 YFU/A<-70C02-Oct-17RT-PCR135000 IU/mLHCVHCV log: 5.1 $95.00Genotype3

Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.

Please read carefully before purchasing:

Clinical specimens for research use only.

Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.

If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341

These products are supplied without warranty for suitability for specific applications or analytical determinations.

Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.